Akebia Therapeutics Inc.
AKBA
Get informed when a big investor buys or sells
+ FollowMarket Cap$273.62M
Close$
$-2.55
363.1% downside
Current Fair Value
363.1% downsideOvervalued by 363.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $273.62 Million |
|---|---|
| Enterprise Value | $127.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 0.35 |
| Outstanding Shares | 267,046,755 |
Return
| Return on Equity | -74.93% |
|---|---|
| Return on Assets | -5.66% |
| Return on Invested Capital | -1.56% |
Valuation & Multiples
| P/E Ratio | -13.28 |
|---|---|
| PEG | 5.35 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.55 |
| Enterprise Value to EBIT | -43.42 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$51.67 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$53.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6749▼ 42.02% |
|---|---|
| Total Calls | 518,300▲ 43.26% |
| Total Puts | 349,800▼ 11.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.55%▼ 5.22% |
|---|---|
| Total Invested | $141.41M▼ 37.00% |
| Investors Holding | 176▲ 2.00% |
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler